Tencent Investment and Guoxin Investment, a state capital investor in Shanghai, have jointly led a Series E funding round of 700 million yuan ($97.4 million) in Chinese biopharmaceutical firm Evopoint Biosciences.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
